Company: RGNX
Filing Date: 2025-01-14
Form Type: 8-K
Source: 0001193125-25-005659
Chunk: 0

Company: REGENXBIO Inc.
Filing Date: 2025-01-14
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01.      Entry into a Material Definitive Agreement.  

On January 14, 2025, REGENXBIO Inc. (the “ Company”) and Nippon Shinyaku Co., Ltd. (“ Nippon Shinyaku“) entered into a Collaboration and License Agreement (the “ Agreement”) for the development and commercialization of RGX-121for the treatment of Mucopolysaccharidosis II (“ MPS II”), also known as Hunter syndrome, andRGX-111for Mucopolysaccharidosis I (“ MPS I”), also known as Hurler syndrome (each, a “ Licensed Product”). The Agreement will become effective upon the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting or suspension period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and any other applicable competition laws.